Jefferies lowered its price target for Arbutus Biopharma (ABUS) to $5.50 from $7.00, citing a chance the company will need to appeal a regulatory decision [2].
The change matters because analysts’ price targets influence institutional buying and selling, and a lower target can pressure the share price, affecting investors who have bet on ABUS’s upcoming clinical milestones.
Jefferies released the revised target on April 7, 2024, after reviewing the likelihood that the company will need to appeal a pending regulatory ruling [1]. The analysts said the appeal probability has risen enough to cut the upside they previously projected. Jefferies cut the price target to $5.50, down from $7.00 [2].
Despite the lower price objective, Jefferies kept a buy rating on ABUS, indicating it still expects the stock to outperform the broader market [2]. The analysts still recommend a buy on ABUS [2].
The appeal risk stems from the U.S. Food and Drug Administration’s recent request for additional data on Arbutus’s gene‑editing therapy, a step that could delay commercialization and revenue expectations. Higher appeal risk trims the stock’s upside potential [2].
Investors typically factor the probability of regulatory setbacks into valuation models; a higher appeal chance reduces the expected net present value of future cash flows, which is reflected in the $5.50 target.
Analysts note that the $5.50 figure remains above the current trading range, suggesting there is still room for upside if the appeal is resolved favorably, but the margin is tighter than the previous $7.00 estimate.
The downgrade aligns with a broader trend of cautious optimism in the biotech sector, where firms often see price‑target adjustments after regulatory developments.
Arbutus Biopharma Corporation (ticker ABUS) focuses on RNA‑based therapeutics and gene‑editing platforms, and its stock has drawn attention following recent FDA interactions.
Jefferies’ research team, which covers U.S. biotech companies, updates price targets as new data emerge, balancing upside potential against regulatory and clinical risks.
An appeal to the FDA can add months to the approval timeline and increase development costs, factors that analysts incorporate when revising valuation assumptions.
For investors, the lowered target signals a more modest near‑term upside, prompting some funds to reconsider position sizes while still maintaining exposure under the buy recommendation.
What this means — The lowered target signals that investors should temper expectations for near‑term gains on ABUS until the appeal outcome is clearer. While Jefferies still sees the stock as a buy, the narrower upside may prompt some funds to reduce exposure, keeping the share’s price range more constrained.
“Jefferies cut the price target to $5.50, down from $7.00.”
The reduced price target indicates that market participants should adjust expectations for Arbutus Biopharma’s short‑term performance, as the higher likelihood of a regulatory appeal compresses the stock’s upside. Although the buy rating remains, the tighter valuation may lead some investors to scale back holdings, limiting price volatility.
